Rigel to Present at the Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq :RIGL ) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Cantor Global Healthcare Conference in New York City on Wednesday, October 3, 2018 at 1:05pm EDT.
The audio presentation will be webcast live and may be accessed on the company's website under the investors section at www.rigel.com, where a copy of the presentation materials will be available for download. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Rigel's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy. In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.
Please see www.TAVALISSE.com for full Prescribing Information.
Contact: David Burke